(MENAFN- Swissinfo) Change is afoot in the upper echelons of Novartis, with Giovanni Caforio set to be elected as the next chair of its board of directors at the 2025 Annual General Meeting.
This content was published on April 23, 2024 - 15:21 2 minutes Keystone-SDA
日本語 ja 製薬大手ノバルティス、次期会長候補に米製薬BMS出身者選出 Read more: 製薬大手ノバルティス、次期会長候補に米製薬BMS出身者選出
He will replace current chair Jörg Reinhardt, who will not stand for re-election in 2025 after a 12-year term of office and will retire as planned.
New chair designate Caforio has spent a large part of his professional career at Bristol Myers Squibb (BMS). He was CEO from May 2015 to November 2023 and served as executive chair from May 2017 to March 2024.
+ Swiss pharma's big bet on Slovenia
Under his leadership, BMS successfully transformed itself into a global medicines company with strong capabilities in research and development as well as commercialisation, Novartis wrote in a statement on Tuesday.
Caforio was born in Italy and is a trained physician. He holds both Italian and US citizenship, and speaks fluent Italian, French, Spanish, Portuguese, and English.
Adapted from German by DeepL/kp/sb
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look
here ,
and if you have feedback on this news story please write to
... .
External Content Your subscription could not be saved. Please try again. Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news
Get the most important news from Switzerland in your inbox.
Daily
Email
The SBC Privacy Policy provides additional information on how your data is processed.
I consent to the use of my data for the SWI swissinfo newsletter.
In compliance with the JTI standards
More: SWI swissinfo certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at ... .
MENAFN23042024000210011054ID1108129290
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.